8-K filing — BIO-TECHNE Corp (TECH)
Filed: 2026-09-23 AccNo: 0001140361-26-037450 Size: 175 KB Item 5.07: Submission of Matters to a Vote of Security Holders Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Bio-Techne Announces SBTi Validation Of 70% Scope 1 & 2 Emissions Reduction Target By FY2031 And Supplier Engagement Commitment, Reporting Significant Operational Emissions Cuts In FY2026
Fiscal 2026 highlights:Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targetsMarket-based Scope 1 and 2 emissions reduced 49% year-over-yearMore than half of the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bio-Techne Receives Shareholders' Approval For Proposed Acquisition By Merck KGaA
Bio-Techne Corporation (NASDAQ:TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the definitive
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
Bio-Techne (TECH) reported Q4 adjusted EPS of 52 cents, meeting consensus estimates but declining 1.9% year-over-year. Full-year adjusted EPS of $1.93 increased 0.5% and surpassed consensus by 1%. Q4 revenues of $321.2 million exceeded estimates by 1.26%, though organic growth was modest at 3%. The company improved its balance sheet with cash increasing to $264.7 million and debt declining to $200 million. However, analysts have issued no estimate revisions in the past two months, and the stock carries a Zacks Rank #3 (Hold) with weak growth and momentum scores.
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger – AUUD, TECH, CZR and CBAN
Monteverde & Associates PC is investigating four major merger and acquisition deals to determine if they are fair to shareholders: Auddia's merger with McCarthy Finney (1:1 stock exchange), Bio-Techne's sale to Merck KGaA ($73/share), Caesars Entertainment's sale to Fertitta Gaming ($31/share plus ticking consideration), and Colony Bankcorp's merger with First Reliance Bancshares ($19.75 cash or 0.94 stock exchange).